女性睾酮使用增加;激素贴剂更新;药物引起的骨质流失
More Women on Testosterone; Hormone Patch Updates; Drug-Induced Bone Loss
女性睾酮使用增加,常无明确诊断;代谢手术后糖尿病复发的预测因素;新药retatrutide在糖尿病治疗中表现优异;FDA更新激素疗法贴剂说明书;医生警告激素疗法增加乳腺癌风险;内分泌学会设立新奖项;多种药物与骨密度下降相关;Eli Lilly扩大GLP-1药物的可及性;美国首个性别重置诊所开放;AstraZeneca拟收购Rhythm Pharmaceuticals及其药物。
— News and commentary from the endocrinology world
November 10, 2026 • 2 min read
Testosterone use among females has risen since 2016 and is frequently prescribed without a documented diagnosis of hypoactive sexual desire disorder, the sole evidence-based indication. (Journal of Clinical Endocrinology & Metabolism)
After type 2 diabetes remission following metabolic-bariatric surgery, predictors of relapse included longer baseline diabetes duration and a greater number of preoperative glucose-lowering medication classes. (Diabetes Care)
In a phase III head-to-head trial, the investigational triple agonist retatrutide showed superior reductions in both HbA1c and body weight compared with semaglutide (Ozempic) in adults with type 2 diabetes, Eli Lilly announced.
The FDA removed boxed warnings about cardiovascular disease, breast cancer, and dementia from prescribing information for more hormone therapy patches for menopausal symptoms. (The Guardian)
Meanwhile, doctors are warning not to overlook the small increase in breast cancer risk associated with certain hormonal therapies for treating menopause symptoms. (New York Times)
The Endocrine Society established a new award honoring late diabetes pioneer Jesse Roth, MD, presenting the inaugural prize to C. Ronald Kahn, MD, of Joslin Diabetes Center and Harvard Medical School in Boston.
What do oral corticosteroids, aromatase inhibitors, androgen deprivation therapy, anti-seizure medications, and selective serotonin reuptake inhibitors have in common? They're all linked to bone density loss. (Washington Post)
Eli Lilly announced a partnership with telehealth platform Hims & Hers Health to expand access to its GLP-1 weight-loss drugs tirzepatide (Zepbound) and orforglipron (Foundayo), offering matched self-pay prices.
The nation's first detransition clinic, at Texas Children's Hospital, is now open, said Attorney General Ken Paxton.
AstraZeneca reportedly offered $10 billion to acquire Rhythm Pharmaceuticals and its first-in-class melanocortin-4 receptor (MC4R) agonist, setmelanotide (Imcivree), for rare genetic obesities. (FiercePharma)
来源:MedPage Today · medpagetoday.com